Tenofovir disoproxil , 98% , 201341-05-1

CAS NO.：201341-05-1

Empirical Formula: C19H30N5O10P

Molecular Weight: 519.44

MDL number: MFCD00952920

EINECS: 606-442-6

PRODUCT Properties

• Boiling point: 642.7±65.0 °C(Predicted)
• Density: 1.45±0.1 g/cm3(Predicted)
• storage temp.: Keep in dark place,Inert atmosphere,2-8°C
• solubility: DMSO: ≥ 38 mg/mL (73.16 mM)
• pka: 4.20±0.10(Predicted)
• form: Solid
• color: White to off-white
• CAS DataBase Reference: 201341-05-1

Description and Uses

Tenofovir disoproxil is a prodrug in a manner similar to that of adefovir dipivoxil. In both cases, the phosphate esters are removed through the action of plasma esterase, leading in this case to tenofovir, which differs from adefovir by the presence of the indicated methyl group. Tenofovir disoproxil exhibits good bioavailability (25%), which is improved in the presence of food (35%). The drug is approved for the treatment of HIV infections in adult patients. Tenofovir diphosphate is an HIV RT inhibitor. The active form of tenofovir is the tenofovir diphosphate, which competes with dATP for incorporation into viral DNA, and when incorporated, tenofovir diphosphate results in premature termination of DNA growth and inhibition of DNA polymerase. Tenofovir disoproxil is indicated for treatment-experienced patients with HIV-1. The drug also appears to be effective in treatment-naive patients, but initial approval is for treatment-experienced patients. The drug is administered as one tablet taken once daily. It is recommended that the drug be combined with other RT inhibitors or HIV PIs, which results in additive or synergistic activity.

Tenofovir Disoproxil is a therapeutic option for nucleos(t)ide analog (NA)-experienced chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV). Also, it is an intermediate used in the synthesis of Tenofovir Disoproxil Dimer (T018515), which is a Tenofovir Disoproxil impurity.